

U.S. Appln. Serial No. 09/826,791
Attorney Docket No. PC10914A

REMARKS

Claims 1, 3-6, 22, 24-26 and 33 are pending in this Application. Claims 2, 7-21, 23 and 27-32 have previously been cancelled. Claims 22, 24-26 and 33 have been allowed. Applicants submit herewith amendments to claims 1, 5 and 6.

The amendments presented herewith follow telephonic interviews with the Examiner on January 31, 2005 and February 18, 2005. The discussion in both interviews was directed to the rejection of claims 1 and 3-6 under 35 U.S.C. §112, first paragraph.

During the interview of January 31, 2005, the Examiner presented her arguments for the rejection of the claims and counsel for Applicant presented Applicant's arguments supporting allowance of the claims.

During the interview of February 18, 2005, there was further discussion regarding the rejected claims. Applicant acknowledges with gratitude the Examiner's assent expressed during the second interview to allow claims 1 and 3-6 following amendments removing the functional language limitation "which encodes a leukotriene receptor that is activated by leukotriene C4 or leukotriene D4", subject to final searching of the specific sequences.


Applicant notes that claim 6 has been further amended for additional clarity of the claim language by the addition of a comma. Applicant submits that the change in punctuation of claim 6 does not constitute the addition of new matter.

Applicant respectfully requests that a timely Notice of Allowance be issued in this Application.

Respectfully submitted,

Date: March 1, 2005

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041



Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,681